IL37 and breast carcinoma: For instance, in breast cancer, circulating IL-37 expression was reported to be highest in ER+/PR+/HER2+ patients compared to PR+ breast cancer patients, emphasizing a potential role in prognosis regulation through ER+/PR+/HER2+ signaling [24].